ENXTPA:SANPharmaceuticals
Sanofi Regulatory Wins And Q1 Strength Versus Weak Share Performance
Sanofi received FDA approval for Tzield to delay type 1 diabetes in children as young as one year old.
The EMA’s CHMP issued a positive opinion for Cenrifki for secondary progressive multiple sclerosis without relapses.
The company reported strong Q1 2026 operational performance, supported by recent pharmaceutical launches and broader business momentum.
These regulatory wins arrive while ENXTPA:SAN trades around €80.08 and has faced a 9.5% decline over the past year, with returns also...